Publications by authors named "Kalevi Kairemo"

Article Synopsis
  • The study aimed to assess how baseline imaging parameters from F-18-fluorodeoxy-D-glucose PET/CT can predict treatment responses in patients with dedifferentiated and well-differentiated liposarcomas.
  • A total of 24 patients were evaluated, with specific parameters like SUVmax, SUVmean, and Hounsfield units calculated from their PET and CT images to measure tumor response to systemic therapy.
  • The research identified that new baseline SUV/HU ratios were effective indicators of treatment outcomes, suggesting changes in SUVmean may provide better insights than traditional metrics alone.
View Article and Find Full Text PDF
Article Synopsis
  • Selective RET inhibitors like selpercatinib and pralsetinib have significantly improved treatment options for cancers caused by RET gene alterations, especially in lung and thyroid cancers.
  • The use of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) has enhanced the way doctors evaluate how well patients respond to these treatments by measuring tumor metabolism.
  • The paper discusses the successful use of RET inhibitors through case studies and highlights the potential of FDG-PET as a non-invasive method to monitor treatment response, while calling for more research to standardize its use in this context.
View Article and Find Full Text PDF
Article Synopsis
  • Prostate cancer (PCa) is a major health issue for men, being the most common cancer and the second leading cause of cancer death, particularly affecting those with metastatic castration-resistant PCa (mCRPC).
  • The study aimed to compare the effectiveness and safety of four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) in treating mCRPC patients through indirect comparisons, addressing a gap in clinical knowledge.
  • A systematic review and network meta-analysis (NMA) were conducted using comprehensive literature searches of multiple databases, ultimately analyzing six high-quality clinical trials that included over 3,200 participants to assess key outcomes like survival rates and adverse effects.
View Article and Find Full Text PDF

The first alpha emitting radiopharmaceutical, RaCl, radium dichloride, was approved 10 years ago into the clinical armament of treating bone metastases in metastatic castration-resistant prostate cancer (mCRPC). In addition to this, the first beta-emitting radionuclide Lu-177 chelated with a prostate-specific membrane antigen (PSMA) compound, got last year its marketing approval for the third line treatment of mCRPC. Therefore, there is great excitement about combining alpha-emitters and prostate cancer targeting PSMA compounds.

View Article and Find Full Text PDF

: The inhibitory effects of tyrosine kinase inhibitors (TKIs) on glucose uptake through their binding to human glucose transporter-1 (GLUT-1) have been well documented. Thus, our research aimed to explore the potential impact of various TKIs of GLUT-1 on the standard [F]FDG-PET monitoring of tumor response in patients. : To achieve this, we conducted an analysis on three patients who were undergoing treatment with different TKIs and harbored actionable alterations.

View Article and Find Full Text PDF

The main aim of this study was to evaluate the current state of bibliometric and altmetric research output of [Ac]Ac-Prostate specific membrane antigen (PSMA) and its implications for prostate cancer (PC). Both PubMed and Scopus digital libraries were systematically explored to retrieve relevant data on the topic of interest. The study of various bibliometric and altmetric indices was facilitated through the use of Microsoft Excel, Stata (Version 17.

View Article and Find Full Text PDF

Serum prostate-specific antigen (PSA) needs to be monitored with ultrasensitive PSA assays (uPSAs) for oncologists to be able to start salvage radiotherapy (SRT) while PSA is <0.5 µg/L for patients with prostate cancer (PCa) relapsing after a radical prostatectomy (RP). Our systematic review (SR) aimed to summarize uPSAs for patients with localized PCa.

View Article and Find Full Text PDF

We review the rationale, methodology, and clinical utility of quantitative [F] sodium fluoride ([F]NaF) positron emission tomography-computed tomography (PET-CT) imaging to measure bone metabolic flux (K, also known as bone plasma clearance), a measurement indicative of the local rate of bone formation at the chosen region of interest. We review the bone remodelling cycle and explain what aspects of bone remodelling are addressed by [F]NaF PET-CT. We explain how the technique works, what measurements are involved, and what makes [F]NaF PET-CT a useful tool for the study of bone remodelling.

View Article and Find Full Text PDF

Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. In this case report, we discuss the case of a patient with a fusion positive bone sarcoma who had exceptional tumor control through using pazopanib and surgery for an overall duration exceeding 5 years. We also review the literature on translocation-associated sarcomas and use of pazopanib in bone sarcomas.

View Article and Find Full Text PDF

Prostate cancer is dependent on the action of steroid hormones on the receptors. Endocrine therapy inhibits hormone production or blocks the receptors, thus providing clinical benefit to many, but not all, oncological patients. It is difficult to predict which patient will benefit from endocrine therapy and which will not.

View Article and Find Full Text PDF

Bone is the most common metastatic site in prostate cancer (PCa). 68Ga-PSMA-11 (or gozetotide) and sodium fluoride-18 (Na18F) are rather new radiopharmaceuticals for assessing PCa-associated bone metastases. Gozetotide uptake reflects cell membrane enzyme activity and the sodium fluoride uptake measures bone mineralization in advanced PCa.

View Article and Find Full Text PDF

Background: 177Lu-PSMA-617 is a promising theragnostic treatment for metastatic castration-resistant prostate cancer (mCRPC). However, both the optimal treatment dose and interval in mCRPC and the rate of identification of responders from non-responders among possible treatment candidates are unknown. Methods: 62 men with mCRPC who were treated with 177Lu-PSMA-617 during 1/2017−2/2019 were included in the study.

View Article and Find Full Text PDF

Thirty-one consecutive patients were included in this study who were planned for parathyroidectomy due to primary hyperparathyroidism. They were studied with US, 4D-CT and dual-phase scintigraphy including SPECT/CT, and possible adenomas were identified in each imaging modality. Imaging data were quantified with US, CT and SPECT.

View Article and Find Full Text PDF

Patients with osteoblastic metastases from high risk osteosarcoma continue to have a poor prognosis after progression from standard-of-care multi-agent chemotherapy. In a first-in-human dose escalation trial of bone targeted Radium 223 dichloride alpha-particle therapy in 18 patients with advanced osteosarcoma only 1 patient responded based on conventional Response Evaluation Criteria in Solid Tumors (RECIST). NaF PET response Criteria in Solid Tumors(NAFCIST), based on Sodium fluoride-18 (NaF) positron emission tomography (PET)-CT was developed to better evaluate bone specific response.

View Article and Find Full Text PDF

In this systematic review and network meta-analysis (NMA), we aimed to assess the benefits and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with metastatic castration-resistant prostate cancer (mCRPC). Two reviewers searched for publications from 1 January 2006 to 30 June 2021. The review analyzed seven RCTs that included 3958 patients and eight treatments.

View Article and Find Full Text PDF

Introduction: Prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) showed in a multicentre WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) study that the presence of bone metastases is a negative prognosticator for the survival. The current multicentre retrospective analysis aims to evaluate the response rate to RLT, the overall survival (OS) of patients and the safety of the treatment according to the extent of bone involvement.

Methods: The study included patients with progressive metastatic castration-resistant prostate cancer (mCRPC), who underwent RLT with [Lu]Lu-PSMA-617 and a follow-up of at least 6 months.

View Article and Find Full Text PDF

Bone metastases are common in prostate cancer (PCa). Fluorocholine-18 (FCH) and sodium fluoride-18 (NaF) have been used to assess PCa associated skeletal disease in thousands of patients by demonstrating different mechanism of uptake-cell membrane (lipid) synthesis and bone mineralization. Here, this difference is characterized quantitatively in detail.

View Article and Find Full Text PDF

Background: The purpose of our study was to find a novel targeted imaging and drug delivery vehicle for inflammatory bowel disease (IBD). IBD is a common and troublesome disease that still lacks effective therapy and imaging options. As an attempt to improve the disease treatment, we tested αMSH for the targeting of nanoliposomes to IBD sites.

View Article and Find Full Text PDF

Background: Pancreatic ductal adenocarcinoma (PDAC), which ranks forth on the cancer-related death statistics still is both a diagnostic and a therapeutic challenge. Adenocarcinoma of the exocrine human pancreas originates in most instances from malignant transformation of ductal epithelial cells, alternatively by Acinar-Ductal Metaplasia (ADM). RA-96 antibody targets to a mucin M1, according to the more recent nomenclature MUC5AC, an extracellular matrix component excreted by PDAC cells.

View Article and Find Full Text PDF

Prostate cancer is the most common cancer to affect men in the United States and the second most common cancer in men worldwide. Prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) imaging has become increasingly popular as a novel molecular imaging technique capable of improving the clinical management of patients with prostate cancer. To date, several Ga and F-labeled PSMA-targeted molecules have shown promising results in imaging patients with recurrent prostate cancer using PET/computed tomography (PET/CT).

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session58ckbvuc4ffqu17mat16qgjf8fasr6b3): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once